158 related articles for article (PubMed ID: 35543754)
1. A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer.
Arigami T; Matsushita D; Okubo K; Shimonosono M; Sasaki K; Tsuruda Y; Kita Y; Tanabe K; Mori S; Yanagita S; Uenosono Y; Nakajo A; Kurahara H; Ohtsuka T
Surg Today; 2022 Dec; 52(12):1721-1730. PubMed ID: 35543754
[TBL] [Abstract][Full Text] [Related]
2. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.
Qiu MZ; Li Q; Wang ZQ; Liu TS; Liu Q; Wei XL; Jin Y; Wang DS; Ren C; Bai L; Zhang DS; Wang FH; Li YH; Xu RH
Int J Cancer; 2014 May; 134(10):2468-77. PubMed ID: 24155030
[TBL] [Abstract][Full Text] [Related]
3. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).
Seo S; Ryu MH; Park YS; Ahn JY; Park Y; Park SR; Ryoo BY; Lee GH; Jung HY; Kang YK
Gastric Cancer; 2019 May; 22(3):527-535. PubMed ID: 30386954
[TBL] [Abstract][Full Text] [Related]
4. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Van Cutsem E; Bang YJ; Feng-Yi F; Xu JM; Lee KW; Jiao SC; Chong JL; López-Sanchez RI; Price T; Gladkov O; Stoss O; Hill J; Ng V; Lehle M; Thomas M; Kiermaier A; Rüschoff J
Gastric Cancer; 2015 Jul; 18(3):476-84. PubMed ID: 25038874
[TBL] [Abstract][Full Text] [Related]
5. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
6. Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer.
Ock CY; Lee KW; Kim JW; Kim JS; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Kim WH; Bang YJ; Oh DY
Clin Cancer Res; 2015 Jun; 21(11):2520-9. PubMed ID: 25712681
[TBL] [Abstract][Full Text] [Related]
7. Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).
Kimura Y; Fujii M; Masuishi T; Nishikawa K; Kunisaki C; Matsusaka S; Segawa Y; Nakamura M; Sasaki K; Nagao N; Hatachi Y; Yuasa Y; Asami S; Takeuchi M; Furukawa H; Nakajima T;
Gastric Cancer; 2018 May; 21(3):421-427. PubMed ID: 28936560
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.
Zhou J; Peng Z; Liu Y; Gong J; Zhang X; Lu M; Gao J; Li Y; Li Y; Shen L
J Gastroenterol; 2015 Sep; 50(9):955-61. PubMed ID: 25702260
[TBL] [Abstract][Full Text] [Related]
9. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy.
Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
[TBL] [Abstract][Full Text] [Related]
10. Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer.
Kijima T; Arigami T; Uenosono Y; Hiraki T; Yanagita S; Matsushita D; Okubo K; Shimonosono M; Ishigami S; Maemura K; Tanimoto A; Natsugoe S
Anticancer Res; 2020 Jan; 40(1):75-80. PubMed ID: 31892554
[TBL] [Abstract][Full Text] [Related]
11. Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications.
Ock CY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
Gastric Cancer; 2016 Apr; 19(2):421-430. PubMed ID: 26002144
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer.
Ryu MH; Yoo C; Kim JG; Ryoo BY; Park YS; Park SR; Han HS; Chung IJ; Song EK; Lee KH; Kang SY; Kang YK
Eur J Cancer; 2015 Mar; 51(4):482-488. PubMed ID: 25661103
[TBL] [Abstract][Full Text] [Related]
14. Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance.
Li Y; Zhang X; Liu D; Gong J; Wang DD; Li S; Peng Z; Li Y; Wang X; Lin PP; Li M; Shen L
Clin Cancer Res; 2018 Nov; 24(21):5261-5271. PubMed ID: 30012565
[No Abstract] [Full Text] [Related]
15. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
Takada M; Higuchi T; Tozuka K; Takei H; Haruta M; Watanabe J; Kasai F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Ogawa S; Kaneko Y
BMC Cancer; 2013 May; 13():241. PubMed ID: 23679233
[TBL] [Abstract][Full Text] [Related]
16. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.
Shah MA; Kang YK; Thuss-Patience PC; Ohtsu A; Ajani JA; Van Cutsem E; Hoersch S; Harle-Yge ML; de Haas SL
Gastric Cancer; 2019 Jul; 22(4):803-816. PubMed ID: 30706247
[TBL] [Abstract][Full Text] [Related]
17. [HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
Bouché O; Penault-Llorca F
Bull Cancer; 2010 Dec; 97(12):1429-40. PubMed ID: 21134821
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study.
Li Q; Jiang H; Li H; Xu R; Shen L; Yu Y; Wang Y; Cui Y; Li W; Yu S; Liu T
Oncotarget; 2016 Aug; 7(31):50656-50665. PubMed ID: 27409420
[TBL] [Abstract][Full Text] [Related]
19. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
